This article is more than 5 years old. Information may no longer be current.
VIDEO: Development of CAR T-cell therapy shifts from lymphoid to myeloid malignancies
Click Here to Manage Email Alerts
The emergence of CAR T-cell therapy for diffuse large B-cell lymphoma and acute lymphocytic leukemia is “a really exciting development” for patients with these cancers, and researchers are now working to determine how this therapeutic approach can be utilized in myeloid malignancies, according to Aaron T. Gerds, MD, MS, of the Cleveland Clinic.
Gerds reviews recent developments in the treatment of acute myeloid leukemia, including the phase 3 RATIFY study of midostaurin (PKC412, Novartis) in patients with FLT3-positive AML, and specific targets that have been investigated for CAR T-cell therapy in AML, including the Lewis-Y antigen and CD33. He also discusses the challenges associated with developing CAR T-cell therapy for myeloid malignancies.
“The major hurdle with … bringing CAR T cells over to AML is finding the right target and … revving up the CAR T cell to really focus in on the malignancy, as opposed to going after the hematopoietic progenitors,” he said.